Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $19.06M rose 89.0% year over year, ahead of the +37.5% change in trailing-twelve-month research & development. Sequentially, it rose 25.8% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +89.0% holds above the trailing-twelve-month pace of +37.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 33.48M USD
- Year-over-year change
- -15.0%
- 4-year CAGR
- +9.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.48M | -15.0% |
| FY2024 | 2024-12-31 | 39.38M | +66.3% |
| FY2023 | 2023-12-31 | 23.68M | +19.4% |
| FY2022 | 2022-12-31 | 19.83M | -13.7% |
| FY2021 | 2021-12-31 | 22.98M | — |
Research & Development vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.5% is the 4th highest of 9, against a peer median of +18.4%.
- Over three fiscal years its annual growth of +19.1% compares with a peer median of +21.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $319.46M USD | -7.3% | -3.1% | 26.6% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 238.42M SEK | +2.0% | +16.0% | 17927.0% |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $147.57M USD | +91.5% | +94.3% | 4442.3% |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M USD | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $58.28M USD | -31.8% | +5.0% | 83.7% | |
| LTM Jun 2026 | $55.75M USD | +34.8% | +26.4% | 12.4% | |
| LTM Sep 2026 | $50.35M USD | +37.5% | +19.1% | — | |
| LTM Mar 2026 | $38.53M USD | +145.2% | +82.5% | — | |
| LTM Mar 2026 | $31.39M USD | -21.6% | -18.9% | 28.6% | |
| Peer median (excluding TRVI) | — | +18.4% | +21.2% | 83.7% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
| Selling, General & Admin | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M |
| Operating Expenses | 32.48M | 29.91M | 33.92M | 51.52M | 49.33M |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| EBITDA | (32.71M) | (27.98M) | (28.58M) | (47.79M) | (42.68M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.48M) | (29.91M) | (33.92M) | (51.52M) | (49.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 10K | 1.74M | 4.75M | 3.6M | 6.54M |
| Interest Expense | 1.2M | 780K | 391K | 4K | 0 |
| Other Income / Expenses | (1.49M) | 719K | 4.83M | 3.58M | 6.51M |
| Income Before Tax | (33.96M) | (29.19M) | (29.1M) | (47.94M) | (42.82M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | (36K) | (32K) | (30K) | (64K) |
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| EPS (Diluted) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| Weighted Avg Shares | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
| Weighted Avg Shares (Diluted) | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.